C. Ola Landgren, M.D. @DrOlaLandgren profile

C. Ola Landgren, M.D.

@DrOlaLandgren

Followers

10,802

Following

91

Media

449

Statuses

4,850

Professor of Medicine, Chief of Myeloma Division & Translational Clinical Oncology Program. Sylvester Comprehensive Cancer Center, Univ of Miami. Tweets = mine

https://t.co/oNSWXZv9mv

Miami, FL

Joined January 2014

Don't wanna be here? Send us removal request.

Explore tweets Explore followers Explore following

Explore trending content on Musk Viewer

FELIX • 185538 Tweets

アザラシ幼稚園 • 132769 Tweets

#Lollapalooza • 86574 Tweets

#SKZpalooza • 85436 Tweets

#SmackDown • 66429 Tweets

STRAY KIDS DOMINATE LOLLA • 62451 Tweets

残高不足 • 42929 Tweets

ロッキン • 42187 Tweets

FGOフェス • 37984 Tweets

#LYKNConcert • 31458 Tweets

Aerosmith • 29402 Tweets

Lamar • 28645 Tweets

オアシス • 26687 Tweets

Key to Moral Values • 25416 Tweets

Ram Rahim • 22365 Tweets

Mahomes • 21474 Tweets

Blake Snell • 19875 Tweets

#Shiorin3D • 19172 Tweets

英霊博装 • 17143 Tweets

オベロン • 15726 Tweets

淀川花火大会 • 12165 Tweets

Tyreek • 10937 Tweets

フェイトブレイカー

アルレッキーノ

मैथिलीशरण गुप्त

奇跡の土日

ピリちゃん

ソロモン

アイチュウ

バスローブ

ロラパルーザ

セッテイロク

適応障害

株価急落

ミリオン11th

エアロスミス

FAMILY CLUB online

Stroman

スタオバ

鼓ちゃん

Jacob Fatu

NISA初心者

Gleyber

レックウザ

そくほー

謎丸シーズン2

謎丸2期

金沢さん

Carille

カノウさん

Last Seen Profiles

@afv1977

@julyrosso

@FanieViljoen2

@jyo_nn

@abd97190946

@WrightSloan

@galleryDAZZLE

@akash21xxx

@H_Kamegai

@Arash_sadeghii

@WasheditFN

@sukkunnnn

@hill_homestead

@danieldruen

@DrakeChart

@ikishitemasuka

@StashInu

@Detective_Ariel

@Coach_Dev

@CuteFemboyFaye

Pinned Tweet

C. Ola Landgren, M.D.

@DrOlaLandgren

10 months

The Myeloma Research Institute at Univ of Miami has a world-class COMPUTATIONAL ONCOLOGY lab focusing on myeloma. We are a global leader in drug development & we provide cutting-edge clinical care. Come join us! #mmsm @IMFmyeloma @theMMRF @HealthtreeMM @SylvesterCancer #IMS23

6

12

79

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Excited to join ⁦ @SylvesterCancer ⁩ & ⁦ @univmiami ⁩ in Miami on Nov 1, 2020 as inaugural Leader of Experimental Therapeutics Program & Leader of Myeloma Program! Forever grateful to ⁦ @sloan_kettering ⁩ for fantastic 6+ yrs #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩

77

25

338

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

YAY!!! Sylvester Comprehensive Cancer Center has received approval to build world-class MYELOMA RESEARCH INSTITUTE in Miami! Truly outstanding for myeloma patients! #mmsm @IMFmyeloma @theMMRF @HealthTreeMM @SylvesterCancer #ASH22 @DrSDNimer @AnnKeilDux

32

22

227

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

JAMA Oncology: Our KRd-daratumumab clinical trial for newly diagnosed multiple myeloma patients online today (MANHATTAN trial), showing 71% MRD negativity in the absence of bone marrow transplant. Unprecedented results! #mmsm @SylvesterCancer @theMMRF @IMFmyeloma @sloan_kettering

JAMA Oncology

@JAMAOnc

3 years

Modern 4-drug combination therapy (carfilzomib-lenalidomide-dexamethasone-daratumumab) is safe, well-tolerated & offers high rates of MRD negativity by itself (ie, in the absence of autologous transplant) in pts w/newly diagnosed multiple myeloma #MMSM

1

23

69

8

41

166

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Outstanding news today for myeloma patients: FDA approves subcutaneous Daratumumab, DARZALEX FASPRO (daratumumab & hyaluronidase-fihj). Fixed-dose injection given in 3 to 5 minutes. Convenient, safe, effective! #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩

Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™...

Company Announcement Subcutaneous formulation of daratumumab, DARZALEX FASPRO™, approved by the U.S. FDA for the treatment of patients with multiple...

www.globenewswire.com

7

47

147

C. Ola Landgren, M.D.

@DrOlaLandgren

1 year

BREAKING NEWS: Today, FDA approved another bispecific BCMAxCD3-targeted monoclonal antibody "Elranatamab" for relapsed/refractory myeloma! Great for patients! #mmsm @IMFmyeloma @theMMRF @HealthtreeMM @ASH_hematology @SylvesterCancer via @onclive

FDA Approves Elranatamab for Relapsed or Refractory Multiple Myeloma

The FDA has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines...

www.onclive.com

2

28

133

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Myeloma is the 2nd most common hematological malignancy globally affecting 450 579 individuals in 2020. We are about to enter a new era with amazing immunotherapies. Great for patients! ⁦ @TheLancet ⁩ ⁦⁦ @dikokaz ⁩ #mmsm ⁦ @SylvesterCancer ⁩

A new era of novel immunotherapies for multiple myeloma

Multiple myeloma is the second most common haematological malignancy globally, with an estimated prevalence of 450 579 cases in 2020.1 Although curative therapy is not yet available, in the past two...

www.thelancet.com

5

37

120

C. Ola Landgren, M.D.

@DrOlaLandgren

4 months

Great victory in myeloma today: ODAC voted 12-0 for MRD as early endpoint for accelerated approval in myeloma Honored to present EVIDENCE meta-analysis, work I pioneered 15 yrs ago. Congrats also to I2TEAMM ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ #mmsm ⁦ @HealthTree ⁩ #myeloma

7

12

114

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Today, we open our new “Myeloma Genomic Laboratory” at Sylvester Comprehensive Cancer Center, Univ of Miami! Lots of exciting research in pipeline! ⁦ @FrancescoMaura4 ⁩ ⁦ @BachisioZic ⁩ @arjun50695688 ⁦ @SylvesterCancer ⁩ #mmsm ⁦ @theMMRF ⁩

10

11

110

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Cancer Surfaceome Atlas: integrates genomic, functional and drug response data to identify actionable targets. Comprehensive, pan-cancer, identification and annotation of genes encoding cell-surface proteins. #mmsm ⁦ @NatureCancer ⁩

0

35

110

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

When at ASH, Vincent and I always meet for a long lunch to discuss meaning of life & non-work things. Friendship & scientific collaboration for almost 20 years. Thank you! @VincentRK ⁩ ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @HealthTreeMM ⁩ #ASH22 ⁦ @MayoClinic ⁩

1

4

105

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

I have decided to change my plans and cancel my in-person attendance at #ASH21 due recent developments with #COVID19 . I will attend the meeting virtually. I look forward to an in-person attendance at #ASH22 . #mmsm @IMFmyeloma @theMMRF @LLSusa @SylvesterCancer

6

4

104

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Very impressive results: Cilta-cel BCMA targeted CAR-T cell therapy for relapsed/refractory multiple myeloma shows 22.8 months median time free of progression - and off all therapy! Great for patients! #ASCO21 @JanssenOncUS #mmsm

Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development

www.businesswire.com

3

28

105

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

"Congrats, MRD negative after completed multiple myeloma combination therapy!" My patient was out fishing north of Miami during telemedicine clinic visit. Modern medicine! @SylvesterCancer #mmsm @theMMRF @IMFmyeloma @myelomacrowd @dikokaz @Denny19 @Drjhoffmanmiami @BenDiamondMD

6

8

101

C. Ola Landgren, M.D.

@DrOlaLandgren

6 years

Poster #3281 is up: modem 4-drug daratumumab-KRd combination for newly diagnosed myeloma. Bone marrow & blood-based MRD. Targeting up to 80% MRD negativity without transplant. Early results with potential to be transformative #ASH18 @sloan_kettering #mmsm @theMMRF @IMFmyeloma

2

24

98

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Cilta-cel CAR T cell therapy was just approved by FDA for multiple myeloma. Deep, sustained clinical responses: durable effect. Great for patients! #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @myelomacrowd ⁩ ⁦ @SylvesterCancer ⁩ ⁦ @JanssenUS ⁩

J&J, Legend cell therapy approved by FDA for multiple myeloma

The CAR-T treatment is the second to be approved in the U.S. for the blood cancer, following Bristol Myers Squibb and 2Seventy bio's Abecma.

www.biopharmadive.com

1

29

96

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

We are thrilled Dr. Dickran Kazandjian will soon join the Myeloma Program at @SylvesterCancer at @UMiamiHealth in Miami! We are expanding our work on novel drugs, dissection of myeloma biology and new MRD assays - aiming to find a cure. Stay tuned! #mmsm @dikokaz @FrancescoMaura4

7

6

91

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Here are my Top 10 #ASH21 @ASH_hematology myeloma abstracts. Links to the full abstract. As in the past, I focus on scientific innovation and clinical high-impact studies. @SylvesterCancer #mmsm @mtmdphd Thread with countdown 👇

1

33

91

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Got my first dose of COVID-19 vaccine today in Miami. Just scheduled my 2nd dose. ⁦⁦ @SylvesterCancer ⁩ ⁦ @UMiamiHealth ⁩ #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @myelomacrowd ⁩

3

9

90

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Thank you very much! I’m honored to join @SylvesterCancer . We will do a of innovative work together. @DrSDNimer @MikkaelSekeres @CraigMoskMD @Drjhoffmanmiami #mmsm

Sylvester Comprehensive Cancer Center

@SylvesterCancer

4 years

Joins us in welcoming @DrOlaLandgren as the leader of a new #research program and the #myeloma team at Sylvester.

7

15

76

5

10

84

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Evidence of strong clinical benefit when using CD38 targeted monoclonal antibody (daratumumab) in two patients with refractory, life-threatening Systemic Lupus Erythematosus (SLE). May become an important treatment strategy for many autoimmune diseases in the future? #mmsm

1

26

86

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Cancer is associated with T cell exhaustion, a hypofunctional state characterized by progressive loss of T cell effector functions and self-renewal capacity. Excellent review on T cell exhaustion in Nature Reviews Clinical Oncology #mmsm ⁦ @theMMRF ⁩

Clinical implications of T cell exhaustion for cancer immunotherapy

Nature Reviews Clinical Oncology - T cells are key effectors of immunotherapies that have revolutionized the treatment of cancer; however, chronic exposure to tumour-associated antigens can result...

www.nature.com

2

23

84

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

When I approached the hospital this morning to do inpatient rounds, this big guy was waiting outside staff entrance area. Had to tell him “sorry, these doors for staff only!” #miamiwildlife ⁦ @SylvesterCancer ⁩ #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @myelomacrowd ⁩

11

3

82

C. Ola Landgren, M.D.

@DrOlaLandgren

5 years

#ASCO19Top10 Myeloma #ASCO19OL : 8005: Dara SC. Big! 8007: AMG420. Wow! 8002: FORTE. Agree! 8057: MyDRUG. Forward! e19537: 4-drugs in NDMM. Future! e19525: Blood MRD. Cool! 8051: Ixa in SMM. Weak! 8024: MRD v FISH. Both! e19505: KRd weekly. Nice! 8026: MRD real-world. Yay! #mmsm

4

28

84

C. Ola Landgren, M.D.

@DrOlaLandgren

8 months

Last night, at ⁦ @SylvesterCancer ⁩ “Miami Nights” event, we announced Dr Damian Green⁩ is joining us as Chief of BMT & Cell Therapy Division. Together, we will expand immunotherapy in Miami! #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ #ash23 ⁩ ⁦⁦ @DrSDNimer ⁩

3

8

83

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Just received my 2nd #COVID19 shot today at ⁦ @UMiamiHealth ⁩ ⁦ @SylvesterCancer in Miami⁩. #IGotTheShot #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @myelomacrowd ⁩

6

4

80

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

We welcome Dr. Marcella Kaddoura aboard as faculty at Myeloma Division at ⁦ @SylvesterCancer ⁩ at Univ of Miami! She joins us from ⁦ @MayoClinic ⁩ & will be our 7th myeloma specialist doctor. #mmsm ⁦ @IMFmyeloma ⁩ #IMS2022 ⁦ @theMMRF ⁩ ⁦ @healthtreeforMM ⁩

4

8

81

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

HAPPY HOLIDAYS to all our patients & their families, collaborators, supporters & friends! Together, we've put MIAMI on the Global Myeloma Map. 2022 was amazing; the best is yet to come! @theMMRF @IMFmyeloma @LLSusa @HealthTreeMM @SylvesterCancer @ASH_hematology #mmsm @OncLive

8

11

77

C. Ola Landgren, M.D.

@DrOlaLandgren

4 months

I started the EVIDENCE meta-analysis in 2009. After 15 yrs of work, I will present 4/12 at ODAC: Can MRD serve as early endpoint for accelerated approval in myeloma, to facilitate patients’ access to new drugs? #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee...

The Committee will discuss the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding t...

www.youtube.com

6

14

75

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Another FDA Approval for Multiple Myeloma: Isatuximab Plus Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma. #mmsm via @onclive

FDA Approves Isatuximab Plus Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma

The FDA has approved isatuximab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received 1 to 3...

www.onclive.com

2

23

72

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Today, the FDA approved first antibody test to detect the coronavirus. Will allow us to determine how many in a population have had the virus and might now be immune. Huge step forward!! #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @sloan_kettering ⁩

FDA approves first antibody test in the US to detect the coronavirus

Antibody tests can help identify people who have already had COVID-19.

www.livescience.com

0

35

71

C. Ola Landgren, M.D.

@DrOlaLandgren

8 months

Thank you very much @ASH_hematology for organizing the #1 annual meeting #ash23 dedicated to hematology. Lots of data & novel ideas. Powerful in-person networking. Now heading home to Miami. See you next year! Happy holidays & safe travels to all friends! #mmsm @SylvesterCancer

4

3

71

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Thank you to the entire Myeloma Program at ⁦ @SylvesterCancer ⁩ in Miami for the fun Holiday Celebrations today! 2021 was a fantastic year for us & I’m excited for 2022! #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @myelomacrowd ⁩ ⁦ @LLSusa ⁩ ⁦ @ASH_hematology ⁩

3

7

73

C. Ola Landgren, M.D.

@DrOlaLandgren

5 months

FDA Approves Bi-weekly Teclistamab Dosing for Relapsed/Refractory Multiple Myeloma via @onclive Reduced dose of 1.5 mg/kg every 2 weeks in patients who achieve & maintain remission (CR) for at least 6 months #mmsm @IMFmyeloma @theMMRF @HealthtreeMM

FDA Approves Bi-weekly Teclistamab Dosing for Relapsed/Refractory Multiple Myeloma

The FDA has approved a supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) at a reduced dose of 1.5 mg/kg every 2 weeks in patients with relapsed/refractory multiple myeloma...

www.onclive.com

1

25

69

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

FDA Approves Melphalan Flufenamide for Relapsed/Refractory Multiple Myeloma via @onclive #mmsm

FDA Approves Melphalan Flufenamide for Relapsed/Refractory Multiple Myeloma

The FDA has approved melphalan flufenamide for use in combination with dexamethasone in the treatment of select adult patients with relapsed/refractory multiple myeloma.

www.onclive.com

3

22

69

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Today in Nature Comm: Accelerated single cell seeding in relapsed myeloma, driven by the survival and subsequent expansion of a single myeloma cell. Seeds rapidly (months). Time to rethink optimal timing of relapse therapy? #mmsm ⁦ @FrancescoMaura4 ⁩

3

25

68

C. Ola Landgren, M.D.

@DrOlaLandgren

1 year

New bispecific MoAb approved for myeloma! Great for patients! FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Myeloma. #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @HealthtreeMM ⁩

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment...

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...

www.prnewswire.com

1

11

65

C. Ola Landgren, M.D.

@DrOlaLandgren

1 year

The Myeloma Research Institute at University of Miami, is a powerhouse when it comes to MRD detection in myeloma. We are one of the global leaders when it comes to innovative science, and we provide top-class clinical care #mmsm @IMFmyeloma @theMMRF @HealthtreeMM @SylvesterCancer

4

18

65

C. Ola Landgren, M.D.

@DrOlaLandgren

7 years

Study Found Hair Repigmentation During PD-1/PD-L1 Immunotherapy: Grey Hair Turned Black. "Immuno-(IO)-Hair-Dye"?!

2

33

47

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Now online in NEJM: “T-Cell Engagers: Modern Immune-Based Therapies for Multiple Myeloma.” Great for Patients with Myeloma! #mmsm @IMFmyeloma @theMMRF @healthtreeforMM @SylvesterCancer @MSKCancerCenter

T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma | NEJM

B-cell maturation antigen (BCMA) was identified as a prognostic marker in multiple myeloma more than two decades ago. Starting in 2014, the first use of BCMA as a treatment target was evaluated in ...

www.nejm.org

0

13

64

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Cancer Discovery: Study shows that CAR T cell treatment induces endogenous T cell memory responses & with feed-forward propagation of CAR T responses. CAR T therapy can shape the microenvironment to have anti-tumor activity #mmsm ⁦ @SylvesterCancer ⁩

1

18

65

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Our Myeloma Program is expanding fast at Sylvester Comprehensive Cancer Center, at University of Miami. Welcome to Miami! #mmsm ⁦ @myelomacrowd ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @SylvesterCancer ⁩ ⁦ @univmiami ⁩ ⁦ @MyelomaTeacher ⁩

Dr. Ola Landgren Sets Up a New Myeloma Shop in Miami - HealthTree for Multiple Myeloma

Dr. Ola Landgren Establishes New Lab and Practice in Miami

healthtree.org

6

64

C. Ola Landgren, M.D.

@DrOlaLandgren

5 years

⁦ @LMCongress ⁩ NYC myeloma session started this morning in NYC! The best annual myeloma meeting - in the city that never sleeps! ⁦ @SLentzsch ⁩ ⁦ @VincentRK ⁩ ⁦ @myelomaMD ⁩ ⁦ @DrGarethMorgan1 ⁩ #LymphomaMyeloma2019 #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩

1

7

64

C. Ola Landgren, M.D.

@DrOlaLandgren

5 years

At Myeloma Service @sloan_kettering every day is a world cancer day 🇺🇸🇹🇷🇵🇱🇪🇸🇳🇪🇮🇷🇫🇷🇷🇺🇨🇦🇨🇴🇿🇦🇯🇲🇨🇳🇲🇦🇮🇪🇳🇴🇸🇪🇮🇹🇬🇷🇮🇱🏳️‍🌈🚩celebrating diversity, treating myeloma patients, providing outstanding care, & driving science with the goal to find a cure! #mmsm @theMMRF @IMFmyeloma @myelomacrowd

2

9

60

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

@drkomanduri @ASH_hematology Our definitive study in @nejm showing that CLL is consistently preceded by a precursor state (MBL) was neither an oral nor a poster at ASH the year before. It was selected as “abstract online only”. At first, we were upset; later I enjoyed not having to put together another talk

0

7

60

C. Ola Landgren, M.D.

@DrOlaLandgren

8 months

We are getting ready for the best social event of @ASH_hematology in San Diego - the “Miami Nights” delivered by @SylvesterCancer at @univmiami ! We will open the gates at 8pm. @DrSDNimer #ash23 @IMFmyeloma @theMMRF @HealthtreeMM @LLSusa @CraigMoskMD @MikkaelSekeres

6

3

60

C. Ola Landgren, M.D.

@DrOlaLandgren

5 years

MSKCC and NYU Myeloma Services develop a new powerful New York City collaboration: “NYC 1st Avenue Myeloma Genomics Program”. Great for patients! @gjmorgan56 @FrancescoMaura4 @malinhultcrantz @EHRustad @myelomacrowd @theMMRF @IMFmyeloma @sloan_kettering @nyulangone #mmsm

2

19

59

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

First professional soccer player vaccinated. #mmsm @theMMRF @IMFmyeloma @SylvesterCancer @UMiamiHealth @FrancescoMaura4 @dikokaz @Drjhoffmanmiami @DrGarethMorgan1 @BenDiamondMD @VincentRK

1

6

59

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Thank you Myeloma Genomic Research lab at Sylvester Comprehensive Cancer Center for fun team building today in South Beach! ⁦ @SylvesterCancer ⁩ ⁦ @FrancescoMaura4 ⁩ ⁦ @BenDiamondMD ⁩ #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @myelomacrowd ⁩

2

7

58

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Wow! Proof of principle that CAR-T therapy can be made in 1 (!) day. Technically possible, but regulatory barriers for FDA approval will likely be hard to overcome #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @healthtreeforMM ⁩ ⁦ @SylvesterCancer ⁩

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

Blood Cancer Journal - Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

www.nature.com

4

26

58

C. Ola Landgren, M.D.

@DrOlaLandgren

7 years

#ASH17 is starting up. The best Hematology meeting of the year. Novel therapies, new disease biology insights, and emerging clinical management concept will presented. Cannot wait! #mmsm @theMMRF @IMFmyeloma @sloan_kettering

1

12

56

C. Ola Landgren, M.D.

@DrOlaLandgren

8 months

Great spending time with longterm friend & colleague Dr ⁦ @NikhilMunshiMD ⁩ from DFCI. Fun talking about MRD testing in myeloma & how it can help moving the field forward with faster drug development #collaboration #teamwork #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ #ash23

1

4

57

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

#ASH22 is getting ready to start in-person in New Orleans. Already seen many myeloma colleagues from around the world. Lots of positive energy & new ideas. Waiting for the meeting to begin! #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @HealthTreeMM ⁩ ⁦ @SylvesterCancer ⁩

2

3

58

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

BREAKING NEWS: The FDA has approved teclistamab-cqyv (Tecvayli) for patients with relapsed/refractory myeloma with at least 4 prior lines of therapy incl proteasome inhibitor, iMID & CD38-targeted antibody #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩

FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy,...

www.onclive.com

1

20

56

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Great congrats Yael, Ido and team! @NatureMedicine ⁩ #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @myelomacrowd ⁩

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients...

Nature Medicine - Integration of longitudinal single-cell analysis of relapsed and refractory multiple myeloma patients in a prospective clinical trial uncovers new pathways of drug resistance and...

www.nature.com

3

20

56

C. Ola Landgren, M.D.

@DrOlaLandgren

1 year

Happy Friday! Miami is on the roll. We have: - Formula 1 - Messi - Sylvester Myeloma Institute at University of Miami Come join us! We are always looking for talent. #mmsm @IMFmyeloma @theMMRF @HealthtreeMM @SylvesterCancer @univmiami @ASH_hematology @LLSusa #miamifl #NYC

2

4

54

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Just landed at MIA in beautiful Miami. Back after 6 hectic days at #ASH22 in New Orleans. Exhausted & filled with lots of new ideas at the same time. After having done ⁦ @ASH_hematology ⁩ virtually for 2 years due to COVID-19, coming back this year was incredible… (1/2)

1

3

55

C. Ola Landgren, M.D.

@DrOlaLandgren

11 months

In collaboration with @MSKCancerCenter , @fredhutch , @NCI , @pmcancercentre , @TischCancer & @DanaFarber we are thrilled to share our recent @NatureComms paper: "Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma" (1/n)

5

9

56

C. Ola Landgren, M.D.

@DrOlaLandgren

1 year

The Myeloma Research Institute at University of Miami has a comprehensive portfolio of CLINICAL TRIALS for patients with myeloma. We are a global leader in drug development, and we provide top-class clinical care! #mmsm @IMFmyeloma @theMMRF @HealthtreeMM @SylvesterCancer #EHA23

3

10

51

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

NYC-Miami Myeloma MRD 2020: Drs Luciano Costa, Ben Derman, Diko Kazandjian, Nina Shah, Ajai Chari, Amrita Krishnan, Elisabet Manasanch, Noa Biran, Paul Richardson, Gareth Morgan, Ruben Niesvizky, Suzanne Lentzsch, James Hoffman, Sundar Jagannath #mmsm @SylvesterCancer @theMMRF

VJHemOnc

@VJHemOnc

4 years

The NYC-Miami Myeloma MRD 2020 Virtual Meeting on the 8th of October brings together leading experts discussing MRD in #Myeloma Register here now! 👉👈 @VJHemOnc #MyelomaMRD20 @sloan_kettering @theMMRF @OncoAlert #MultipleMyeloma #mmMRD #OncoAlert

1

6

14

0

15

54

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Every night at 7PM, New Yorkers join in unison to open their windows & offer a round of applause to healthcare workers who have stepped forward to meet the challenges of COVID-19. Thank you to all colleagues, NPs, nurses, PharmDs & staff for your relentless dedication! #mmsm

1

7

55

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

First trucks carrying the COVID-19 vaccine in the US have left the Pfizer facility

2

5

54

C. Ola Landgren, M.D.

@DrOlaLandgren

5 years

Unprecedented MRD negativity rates in newly diagnosed multiple myeloma with weekly KRd-D combination therapy. Great for patients! ⁦ @VJHemOnc ⁩ #mmsm

Unprecedented MRD negativity in NDMM with weekly KRd-D

Ola Landgren, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results from a phase II clinical and correlative study (NCT03290950) of weekly carfilzomib, lenalidomide,...

www.vjhemonc.com

2

18

54

C. Ola Landgren, M.D.

@DrOlaLandgren

5 years

MSKCC and NYU Myeloma Services powerful New York City collaboration: “NYC 1st Avenue Myeloma Genomics Program”. Exciting scientific meeting today! @DrGarethMorgan1 @FrancescoMaura4 @malinhultcrantz @EHRustad @myelomacrowd @theMMRF @IMFmyeloma @sloan_kettering @nyulangone #mmsm

2

7

54

C. Ola Landgren, M.D.

@DrOlaLandgren

1 year

Sylvester Myeloma Institute at @SylvesterCancer & Division of Myeloma at @UniversityMiami -- Research Strategy Retreat 2023 in beautiful Miami. The Myeloma Program is moving fast forward. The best is yet to come! #mmsm @IMFmyeloma @theMMRF @HealthtreeMM @ASH_hematology #myeloma

0

8

52

C. Ola Landgren, M.D.

@DrOlaLandgren

4 months

It was an honor to present the EVIDENCE meta-analysis at ODAC last week, work I pioneered 15 yrs ago. It will give pts rapid access to new, effective myeloma drugs. Being back in clinic this week with my team feels great! @IMFmyeloma @theMMRF @HealthTree #mmsm @SylvesterCancer

4

2

54

C. Ola Landgren, M.D.

@DrOlaLandgren

1 year

ChromoSeq - first whole-genome sequencing test for cancer is approved for reimbursement by Medicare. This opens doors for precision medicine in the clinic - GREAT! #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @HealthtreeMM ⁩ ⁦ @SylvesterCancer ⁩

Medicare approves WashU Medicine’s whole-genome test for blood cancers | Washington University...

Complete picture of genetic errors can advance precision medicine approaches to treatment

medicine.wustl.edu

0

14

52

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

#ASH22 Dr Diamond gives an outstanding talk on mechanisms of melphalan-induced second primary malignancies. Strong work, great congrats @BenDiamondMD ! #mmsm @theMMRF @IMFmyeloma @HealthTreeMM @SylvesterCancer @FrancescoMaura4 @dikokaz

3

10

53

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Good day at #ASH22 today: our Myeloma Institute genomic lab just finished the 5th oral presentation of the day! Congrats to entire team! ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @HealthTreeMM ⁩ ⁦ @SylvesterCancer ⁩

4

3

52

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Last “Myeloma Genomic Research Lab Meeting” of 2020. Staying 2 arm lengths apart. Plans for 2021 are ambitious. Stay tuned! ⁦ @FrancescoMaura4 ⁩ ⁩⁩ ⁦⁩⁦ @SylvesterCancer ⁩ ⁦ @UMiamiHealth ⁩ #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @myelomacrowd ⁩

0

4

50

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Dr. Nimer⁩ is kicking off the Annual Retreat for Sylvester Comprehensive Cancer Center. A scientific powerhouse in beautiful Miami. Visionary leadership, hard work & dedication: teamwork for innovation. Great for patients! ⁦ @SylvesterCancer ⁩ ⁦ @DrSDNimer ⁦ #mmsm

0

7

49

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Sylvester Comprehensive Cancer Center, University of Miami has great representation at #ASH22 . Many oral presentations & lots of posters - fueled by the outstanding vision & leadership of ⁦ @DrSDNimer ⁩! #mmsm ⁦ @dikokaz ⁩ ⁦ @SylvesterCancer ⁩ ⁦ @univmiami ⁩

1

8

52

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Idecabtagene Vicleucel CAR T Cells in Relapsed and Refractory Multiple Myeloma | NEJM #mmsm

3

15

49

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Dynamics of MRD in patients with myeloma on continuous lenalidomide maintenance. Serial measurements of MRD allow for dynamic assessment of risk for progression. Early intervention should be investigated for patients with loss of MRD negativity #mmsm

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide...

Serial measurements of MRD allow for dynamic assessment of risk for disease progression. Early intervention should be investigated for patients with loss of MRD negativity. Sustained MRD positivity...

www.thelancet.com

3

11

50

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Happy New Year! Janssen has filed bi-specific antibody (BCMA/CD3) “Teclistamab” to FDA for the treatment of relapsed/refractory multiple myeloma: based on the results of the phase 1b MajesTEC-1 study (3+ prior lines of therapy). Great for patients! #mmsm

J&J goes after another FDA approval for a cancer bispecific

Johnson & Johnson's much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and the drugmaker has now filed for FDA approval of a second candidate. The...

pharmaphorum.com

1

13

48

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

New innovative class of immunotherapy drugs - trispecific antibodies (targeting 3 antigens) - is opening up in myeloma care. We have it at Myeloma Program at @SylvesterCancer in Miami. For patients with relapsed/refractory myeloma. #mmsm @myelomacrowd @IMFmyeloma @theMMRF

HealthTree Foundation

@HealthTree

2 years

A new class of drug called trispecific antibodies is opening up in myeloma care with a new announcement by Ichonos Sciences. #mmsm #myeloma #HealthTreeMM

1

6

21

4

12

50

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Today, we celebrated the launching of our new Myeloma Division at @SylvesterCancer @univmiami in beautiful Miami! We are thrilled to have 8 accepted oral presentations at upcoming #ASH22 in New Orleans in Dec. Congrats team! #mmsm @theMMRF @IMFmyeloma @HealthTreeMM @DrSDNimer

5

6

50

C. Ola Landgren, M.D.

@DrOlaLandgren

7 years

#Myeloma sessions are very well attended at #ASH17 . Lots of new data in a rapidly changing field. #MMSM

1

17

47

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

The Myeloma Research Team at @SylvesterCancer at @univmiami strikes again! Thank you all for fun social event this week. Cutting-edge genomic science, translational research, drug development, strong teamwork & great friendship! #mmsm @IMFmyeloma @theMMRF @myelomacrowd @DrSDNimer

4

6

50

C. Ola Landgren, M.D.

@DrOlaLandgren

4 months

In a ‘Historical’ Moment FDA Committee Rules on a Faster Way to Approve Therapies for Myeloma Honored to present EVIDENCE meta-analysis, work I pioneered 15 yrs ago. Congrats also to I2TEAMM @IMFmyeloma @theMMRF #mmsm @HealthTree ⁦ @SylvesterCancer ⁩

In a “Historic” Moment, FDA Committee Rules on a Faster Way to Approve Therapies for Multiple...

An FDA advisory committee voted yes on how the agency evaluates new treatments for multiple myeloma, based on Sylvester research.

news.med.miami.edu

2

6

49

C. Ola Landgren, M.D.

@DrOlaLandgren

9 months

We are launching a NEW COMPUTATIONAL ONCOLOGY FELLOWSHIP/POST-DOC program at University of Miami! This NEW position has been created to accelerate research on high-risk myeloma with emphasis on the t(4;14) subtype If you are interested in this opportunity, send us a DM! (1/X)

4

5

49

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Thank you Myeloma Program @SylvesterCancer at @univmiami for a fun team building event today at @TheBerryFarms in Miami! #mmsm @IMFmyeloma @theMMRF @myelomacrowd #strawberrypicking #sunflowers #outdoorlunch #smoothies

2

5

47

C. Ola Landgren, M.D.

@DrOlaLandgren

4 months

Inaugural Precision Medicine in Myeloma conference launched this past weekend in Miami Beach: what a success! >100 attendees. Back next year! Thank you Drs Kumar, Fonseca, Green, Shain, Richardson, Kazandjian & Diamond for speaking! @SylvesterCancer #mmsm @theMMRF @IMFmyeloma

0

6

48

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Lifetime pesticide use and risk of myeloma precursor disease (MGUS): a prospective study. Excess risk associated with permethrin, an insecticide with continued widespread use in residential & commercial settings. #mmsm ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩

Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective...

This is the largest investigation of MGUS in farmers and the first to identify an association with MGUS for permethrin, a pyrethroid insecticide previously associated with multiple myeloma. Given the...

pubmed.ncbi.nlm.nih.gov

1

13

47

C. Ola Landgren, M.D.

@DrOlaLandgren

5 years

#ASH19 is completed. Great meeting. Fun to meet old & new friends! Lots of advances in our understanding of myeloma biology, new clinical data, early leads for new drug targets, & more! Now back home in city that never sleeps. Tomorrow we will start prepping for #ASH20 #mmsm

2

4

48

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Important new paper on how to interpret serum free light chains (FLCs): Defining new reference intervals for serum FLCs in individuals with chronic kidney disease: Results of… #mmsm @IMFmyeloma @theMMRF @healthtreeforMM @SylvesterCancer @sykristinsson

Defining new reference intervals for serum free light chains in individuals with chronic kidney...

Serum free light chain (FLC) concentration is greatly affected by kidney function. Using a large prospective population-based cohort, we aimed to establish a reference interval for FLCs in persons...

pubmed.ncbi.nlm.nih.gov

0

21

46

C. Ola Landgren, M.D.

@DrOlaLandgren

4 months

Yesterday, in a ‘Historical’ Moment, FDA Committee Ruled on a Faster Way to Approve Therapies for Myeloma. We were honored to present EVIDENCE meta-analysis, work I pioneered 15 yrs ago. Congrats also to I2TEAMM! @IMFmyeloma @theMMRF #mmsm @HealthTree @SylvesterCancer

International Myeloma Foundation

@IMFmyeloma

4 months

IMF celebrates ODAC's historic decision on MRD testing as an early endpoint for accelerated myeloma drug approval. 10 yrs of IMF research led by Dr. Durie & i2TEAMM; & U of Miami Sylvester Comprehensive Cancer Center contributed to this decision. @BrunoPaiva_UNAV @NikhilMunshiMD

1

21

75

6

8

48

C. Ola Landgren, M.D.

@DrOlaLandgren

4 months

CARVYKTI (cilta-cel) Becomes First and Only BCMA-Targeted CAR-T Cell Therapy FDA Approved for 2nd-Line Treatment of Myeloma #mmsm ⁦ @SylvesterCancer ⁩ ⁦ @theMMRF ⁩ ⁦ @IMFmyeloma ⁩ ⁦ @HealthTree ⁩ ⁦ @LLSusa ⁩ ⁦ @ASH_hematology ⁩

2

15

46

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Teclistamab BCMA-CD3 targeted bispecific monoclonal antibody was just approved in Europe for the treatment of multiple myeloma. A huge step forward for individual patients and for the field overall! #mmsm @IMFmyeloma @theMMRF @healthtreeforMM @SylvesterCancer

J&J Innovative Medicine

@JNJInnovMed

2 years

We're pleased to announce the European Commission granted a Conditional Marketing Authorization for our latest #multiplemyeloma treatment. #MMSM

0

13

35

0

11

45

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

Two new studies reveal people infected with SARS-CoV-2 harbor T cells targeting the virus. Some people never infected with SARS-CoV-2 also have these cellular defenses, likely due to infection(s) with other coronaviruses. Bodes well for long-term immunity

1

12

48

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

New paper by our lab: Copy number variation signatures predict whether myeloma patients have catastrophically smashed and aberrantly reassembled chromosomes (chromothripsis). Better understanding of patient’s risk and guidances of treatment @FrancescoMaura4 #mmsm @NatureComms

Sylvester Comprehensive Cancer Center

@SylvesterCancer

3 years

In a paper published in @NatureComms , @FrancescoMaura4 and @DrOlaLandgren illuminate shattered chromosomes in Multiple Myeloma. Read more: #cancerresearch #cancercare #sylvestercancer #myeloma #research #medicine #cancer #healthcare

0

4

10

1

7

46

C. Ola Landgren, M.D.

@DrOlaLandgren

4 years

FIrst ADC drug for myeloma patients. First BCMA-targeted drug for myeloma patients. FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma. #mmsm

1

14

47

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Thank you Myeloma Division ⁦ @SylvesterCancer ⁩ ⁦ @univmiami ⁩ for a great retreat! Thanks for all you do for our pts + for innovative science. I’m very happy to be part of this team! #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @HealthTreeMM ⁩ ⁦ @ASH_hematology ⁩

1

5

46

C. Ola Landgren, M.D.

@DrOlaLandgren

8 months

At @ash23 Dr. Elisabeth Hill gave strong talk focusing on ⁦ @theNCI ⁩ trial with KRd (8 cycles) + 2 yrs of lenalidomide for patients with high-riskSMM. Amazing to see how 70% of patients sustain MRD negativity at 8 years of follow up #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩

2

8

47

C. Ola Landgren, M.D.

@DrOlaLandgren

11 months

BREAKING NEWS!⁦ @NatureMedicine ⁩ study shows mechanisms of resistance to BCMA- or GPRC5D-targeted immunotherapies in myeloma #mmsm @hollyleeYJ @FrancescoMaura4 @NBahlis ⁦ @IMFmyeloma ⁩ @theMMRF ⁩ ⁦ @HealthtreeMM ⁩ ⁦ @SylvesterCancer ⁩

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

Nature Medicine - Tumor-intrinsic resistance mechanisms, including mutational events and immunoselection of mutant clones, were identified in 30 patients with multiple myeloma who experienced...

www.nature.com

1

6

46

C. Ola Landgren, M.D.

@DrOlaLandgren

2 months

Getting ready together with ⁦ @Mohty_EBMT ⁩ for tomorrow’s opening session at #EHA2024 in Madrid, Spain. We will cover the latest news on bispecific monoclonal antibodies in myeloma! ⁦ #mmsm ⁦ @IMFmyeloma ⁩ ⁦ @theMMRF ⁩ ⁦ @HealthTree ⁩ ⁦ @SylvesterCancer ⁩

1

7

46

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

New CDC guidelines for moderately or severely immunocompromised individuals in the US: 4 doses of COVID vaccines. Primary series (2 doses), an additional dose (3rd dose), & then an additional booster 6 months later (4th dose). See here: … #mmsm

3

17

46

C. Ola Landgren, M.D.

@DrOlaLandgren

9 months

At #ASH23 in San Diego in Dec 2023, the Myeloma Institute at Univ of Miami will give several oral presentations and participate in many collaborative myeloma talks. Congrats to everybody who has contributed. Here is a list of presenters and topics, as well as links to abstract:

2

11

46

C. Ola Landgren, M.D.

@DrOlaLandgren

2 years

Yes, we need to challenge the dogma of myeloma being incurable. INCORRECT: Myeloma is incurable. CORRECT: We do not yet have established curative therapies for myeloma. We are working on it! #mmsm @IMFmyeloma @theMMRF @healthtreeforMM #IMS2022 @ASH_hematology @SylvesterCancer

Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽

@Rfonsi1

2 years

⁦ @mvmateos ⁩ “We need to challenge the dogma of myeloma being incurable” Agree 100%! We are curing some patients today. We just don’t yet who and how many. #IMS2022 #mmsm

1

17

95

1

11

44

C. Ola Landgren, M.D.

@DrOlaLandgren

3 years

Join us on April 24 at 6.30-8.00PM ET. “Institutional Perspectives in Cancer: Multiple Myeloma”. Register for free: Live webinar from Miami! @UMiamiHealth @SylvesterCancer @OncLive @dikokaz @Drjhoffmanmiami @BenDiamondMD @FrancescoMaura4 #mmsm @IMFmyeloma

2

14

44